Oncology


Online Activities

Oncology Exchange: Personalizing Treatment for NSCLC

Program type


This on-demand CME-certified webcourse uses clinical case scenarios to provide guidance on the optimal treatment algorithms for the management of NSCLC, while also exploring issues faced by community clinicians involved in the treatment of patients with NSCLC.

Revolutionizing Treatment Strategies for Advanced Breast Cancer

Program type


This on-demand CME-certified webcourse will update community clinicians on the emerging data and quality measures related to the management of recurrent breast cancer, in order to ultimately improve patient outcomes.

Oncology Exchange: Current Treatment Strategies for Chronic Myelogenous Leukemia

Program type


This on-demand CME webcourse uses clinical case scenarios to provide guidance on optimal treatment algorithms for the management of chronic myelogenous leukemia (CML) and explores common issues faced by clinicians involved in the treatment of CML patients.

Emerging Agents in Her2-positive Breast Cancer

This is a Grand Rounds Program


This new CME-certified in-hospital grand rounds program provides clinicians with information on emerging agents in Her2-positive breast cancer and how they can be integrated into their practices to improve patient outcomes.

Frontline Treatment Options in Multiple Myeloma: An Oncology Exchange Activity

This is a Grand Rounds Program


This new CME-certified in-hospital grand rounds program provides clinicians with information on new frontline treatment options for multiple myeloma and insights on how they can be integrated into their practices to improve patient outcomes.

Emerging Agents in Her2-positive Breast Cancer

This is a Grand Rounds Program


This new CME-certified in-hospital grand rounds program provides clinicians with information on emerging agents in Her2-positive breast cancer and how they can be integrated into their practices to improve patient outcomes.

Emerging Strategies in Relapsed/Refractory Non-Hodgkin’s Lymphoma

This is a Grand Rounds Program


This new CME-certified in-hospital grand rounds program provides clinicians with information on emerging strategies in relapsed/refractory non-hodgkin’s lymphoma and how they can be integrated into their practices to improve patient outcomes.

CONSIDERATIONS FOR PRACTICE: WOMEN AND LUNG CANCER

Program Type


This CME/CE certified webcourse is designed to increase awareness of the role of gender in the individualization of care for NSCLC patients. Current best practices that can improve outcomes are explored.

CLINICAL CONSULTS IN SARCOMA: A CASE-BASED CME ACTIVITY

Program Type


This case-based webcourse reviews the diagnosis and classification of sarcomas and the timing for referral to a specialty center; explains the updated NCCN clinical guidelines for diagnosis and treatment and how to plan a multidisciplinary treatment approach; and discusses ongoing trials and emerging data from novel treatment regimens.

Therapeutic Advances in non-small cell Lung Cancer: Case 4

Program Type


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.

Therapeutic Advances in non-small cell Lung Cancer: Case 3

Program Type


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.


Therapeutic Advances in non-small cell Lung Cancer: Case 2

Program Type


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.


Therapeutic Advances in non-small cell Lung Cancer: Case 1

Program Type


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.


Therapeutic Advances in non-small cell Lung Cancer

Program Type


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.


OPTIMIZING THE CONTINUUM OF CARE FOR MYELODYSPLASTIC SYNDROMES

A series of four multidisciplinary webcourses on the diagnosis and treatment of patients with myelodysplastic syndromes (MDS).
  Making A Definitive Diagnosis of MDS Learn More
  Anemia Differentiation in the Elderly: When to Refer Learn More
  Management of Patients with IPSS Low/Int-1-Risk MDS Learn More
  Management of Patients with IPSS Int-2/High Risk MDS Learn More


TARGETING GIST: EVOLVING THERAPY

This CME-certified online monograph reviews the distinct management strategies that have emerged for patients with primary GIST that can easily be surgically removed as well as for those with locally advanced, recurrent, or metastatic GIST.
Learn More


THE EVOLVING ROLE OF MICROTUBULE INHIBITORS IN ADVANCED BREAST CANCER

This CME-certified webcourse reviews the current and emerging clinical data to define best practices for the management of patients with advanced breast cancer using microtubule-inhibitors.
Learn More


Live Activities

Novel Therapeutic Approaches for Stage III and Stage IV Melanoma

This is a Live Event. View this activity to register.


With the recent approval of many novel agents there have been significant changes in the treatment landscape for melanoma. Surgical oncologists, plastic surgeons, and ENT and general surgeons play a crucial role in the diagnosis, staging, and management of melanoma.

Multimodality Treatments for Advanced Basal Cell Carcinoma
A CME-certified and MOC Part II eligible Symposium

This is a Live Event. View this activity to register.


A live symposium designed to help surgical oncologists understand the role of multimodality therapies in the management of BCC, and to incorporate recent evidence-based therapeutic regimens into clinical practice, ultimately leading to improved patient outcomes.


HIDDEN AREA

TextAreaId:
TextAreaName:
SubFolderPath:
Control Mode: